3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment MarketBeat · Sep 24, 2025
FDA approval of Narcan as over-the-counter drug will boost accessibility, save lives, health officials say BALTIMORE — As soon as this summer, people will be able to purchase the opioid overdose reversal medication Narcan as easily as they can buy Tylenol and Benadryl, after the U.S. Food and Drug Administration approved it last week to be sold over the counter. Tribune News Service · Apr 5, 2023
Over-the-counter Narcan will save lives, experts say. But the cost will affect access Advisers to the FDA put the opioid overdose-reversal drug a step closer to being sold without a needing a prescription. Even if approved, the medication may not reach many people who need it. WEKU · Feb 18, 2023
FDA panel weighs moving opioid antidote over the counter U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication The Independent UK · Feb 15, 2023
A major drugmaker plans to sell overdose-reversal nasal spray Narcan over the counter Emergent BioSolutions has applied to the Food and Drug Administration to sell the opioid overdose-reversal drug over the counter. Addiction experts say it may be a key step to lower fentanyl deaths. WEKU · Dec 13, 2022
The FDA Is Doing Something That Could Actually Cut Overdose Deaths Naloxone could be available without a prescription by spring. Reason · Dec 12, 2022
At concert outside Baltimore plant, musicians protest Maryland pharmaceutical company’s Narcan prices BALTIMORE — Joined by harm-reduction advocates, local musicians performed outside a Baltimore drug manufacturing facility Wednesday afternoon to protest the price of the overdose-reversing drug Narcan sold by pharmaceutical company Emergent BioSolutions. Tribune News Service · Oct 27, 2022
More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response. Tribune News Service · Aug 11, 2022
U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory agency sets the Prescription Drug User Fee Act (PDUFA) goal date for a decision in month of April 2023. Benzinga · Jun 24, 2022
Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines. Benzinga · Jun 6, 2022
Why Emergent Biosolutions Stock Is Rising Today Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Monday amid increasing monkeypox concerns. Benzinga · May 23, 2022
400 million COVID-19 vaccine doses dumped by Baltimore plant, congressional report finds BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known. Tribune News Service · May 10, 2022
Benzinga · Feb 24, 2022 Emergent BioSolutions: Q4 Earnings Insights Emergent BioSolutions (NYSE:EBS) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.